SCHEMBL1490917

SCHEMBL1490917

[O]c1ccccc1NC(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 2/20 0.63
TP53 P04637 2/20 0.63
HDAC3 O15379 2/20 0.63
HDAC1 Q13547 2/20 0.63
HDAC2 Q92769 2/20 0.63
HPGD P15428 2/20 0.63
MAPK1 P28482 1/20 0.63
POLB P06746 1/20 0.63
MAPT P10636 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
PKM P14618 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110180 0.87 MDM4 (0.73) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL3790102 0.82 NPC1 (0.68) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL19509669 0.81 HDAC3 (0.66) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL6067716 0.81 HDAC1 (0.66) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL10953014 0.81 HDAC3 (0.71) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL10828925 0.80 RAB9A (0.45) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL34933 0.80 TDP1 (0.72) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL1023209 0.80 MAPT (0.83) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL4946074 0.79 NPC1 (0.73) MDM4TP53HDAC3HDAC1HDAC2
SCHEMBL6288808 0.79 HDAC3 (0.63) MDM4TP53HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992016233-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO claimed
EP-0100051-B1 NEW DERIVATIVES OF 1-ALKYLAMINE-(4(P-ALKYLOXY-BENZAMIDE)PHENOXY)-2-PROPANOL, HAVING BETA-SYMPATHOLYTIC ACTIVITY, THEIR SALTS, AND PRODUCTION PROCESSES THEREOF A. Menarini S.a.S. (IT) 1986-04-09 EP claimed
EP-0100051-A1 New derivatives of 1-alkylamine-(4(p-alkyloxy-benzamide)phenoxy)-2-propanol, having beta-sympatholytic activity, their salts, and production processes thereof A. Menarini S.a.S. (IT) 1984-02-08 EP claimed
US-8765961-B2 Near infrared fluorescent imaging agent FUJIFILM CORPORATION (JP) 2014-07-01 US disclosed
US-20110054188-A1 NEAR INFRARED FLUORESCENT IMAGING AGENT FUJIFILM CORPORATION (JP) 2011-03-03 US disclosed
US-20110054181-A1 NEAR INFRARED FLUORESCENT IMAGING AGENT FUJIFILM CORPORATION (JP) 2011-03-03 US disclosed
EP-2289563-A1 Near infrared fluorescent imaging agent Fujifilm Corporation (JP) 2011-03-02 EP disclosed
EP-2289562-A1 Near infrared fluorescent imaging agent Fujifilm Corporation (JP) 2011-03-02 EP disclosed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP disclosed
EP-0459349-B1 Silver halide color negative photosensitive material FUJI PHOTO FILM CO LTD (JP) 1997-03-26 EP disclosed
EP-0294035-B1 Benzoylaminophenoxybutanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1994-08-31 EP disclosed
US-5254446-A Pyrazoloazole magenta coupler; sharpness FUJI PHOTO FILM CO., LTD. (JP) 1993-10-19 US disclosed
EP-0291245-B1 BENZOYLAMINOPHENOXYBUTANOIC ACID DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1992-07-22 EP disclosed
EP-0459349-A1 Silver halide color negative photosensitive material FUJI PHOTO FILM CO., LTD. (JP) 1991-12-04 EP disclosed
EP-0456257-A1 Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1991-11-13 EP disclosed
EP-0294035-A2 Benzoylaminophenoxybutanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1988-12-07 EP disclosed
EP-0291245-A2 Benzoylaminophenoxybutanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1988-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054181-A1 NEAR INFRARED FLUORESCENT IMAGING AGENT MSR1, RXFP1, IK MDM4 2527/4885TP53 1982/4885HDAC3 786/4885
US-20110054188-A1 NEAR INFRARED FLUORESCENT IMAGING AGENT MSR1, IK, RXFP1 MDM4 2092/4885TP53 1347/4885HDAC3 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.